Gambaran Penggunaan Antıhıpertensı pada Pasıen ST- Elevatıon Myocardıal Infractıon

Khofifah aulia; Irma  Novrianti; Jufri Ubrusun

doi:10.57174/jborn.v2i1.65

Authors

Khofifah aulia a:1:{s:5:"en_US";s:18:"Politeknik kaltara";}
Irma Novrianti Politeknik Kaltara
Jufri Ubrusun Politeknik Kaltara

DOI:

https://doi.org/10.57174/jborn.v2i1.65

Keywords:

antihypertensives, blood pressure classification, STEMI

Abstract

ST-Elevation Myocardial Infraction (STEMI) is caused by several factors, mainly due to cardiovascular disorders. There are several complaints from STEMI, such as chest pain, elevated enzymes, and ST elevation on electrocardiogram examination. One of the major factors in the occurrence of STEMI is hypertension. The more severe the hypertension condition will slowly damage the blood vessel walls causing swelling, which leads to STEMI. This study aimed to see the use of antihypertensives in stemmy patients who were using fibrinolytic therapy. This research method is descriptive retrospective by looking at the medical records of STEMI patients who received antihypertensive treatment at the Emergency Room (ER) and were hospitalized at Tarakan City "X" Hospital for the 2017-2018 period. Based on the research, it was found that 55 patients used antihypertensives. The highest classification of blood pressure when admitted to the hospital was in stage II conditions based on JNC VII in 15 people (27.28%), and the classification of blood pressure when leaving the hospital was found to be in normal condition in 23 people (41.82%). The most antihypertensive used in "X" Hospital in Tarakan city is the ACE-Inhibitor group, namely captopril, with a percentage of 10.90% in the ER, and the Beta blocker group, namely bisoprolol fumarate with a percentage of 65.46% in the Inpatient Room.

Downloads

Download data is not yet available.

References

Barangkau, Sargowo D, Suharsono T. Faktor Risiko Penderita Sindroma Akut Terhadap Lama Perawatan kritis Dan Angka Kematian. DK. 2013;1(2):1–10.

Agustina. ST Elevasi Miokard Infark (STEMI) pada laki-laki 40 tahun. J Keperawatan Med Bedah. 2013;

Rathore V. Risk Factors of Acute Myocardial Infarction: A Review. Eurasian J Med Investig. 2018;2(1):1–7.

Hermanides RS, Kilic S, van ’t Hof AWJ. Optimal pharmacological therapy in ST-elevation myocardial infarction—a review: A review of antithrombotic therapies in STEMI. Netherlands Hear J. 2018;26(6):296–310.

Novrianti I, Wijaya D, Mustamin F, Wijayanti S. Pharmacological Therapy for ST-Segment Elevation Myocardial Infarction: A Review. J Islam Pharm [Internet]. 2020;5(2):9–13. Available from: http://ejournal.uin-malang.ac.id/index.php/jip/article/view/8989/8226

Laksono BB. Literature Review Efektifitas Terapi Fibrinolitik Dan Ppci ( Primary Percutaneus Corornary Intervention ) Sebagai Alternative Terapi Revaskulerisasi Pada Acute Coronary Syndrome ( Acs ). 2015;3(Mi):62–8.

Price S, Wilson L. Patofisiologi: konsepklinis prosesproses penyakit Edisi ke-6. In: 6Th ed. Jakarta: EGC; 2006.

Wechsler H, Levine S, Idelson RK, Rohman M, Taylor JO. The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF OTAGO on May 20, 2014. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights reserved. N Engl J Med. 1983;308(2):97–100.

Winanda D, Prabowo WC, Rusli R. Pola Pengobatan Pada Pasien Infark Miokard Akut Di Rumah Sakit Abdul Wahab Sjahranie Samarinda. Proceeding Mulawarman Pharm Conf. 2019;10:94–9.

Yuliarti. Mayo Clinic Hipertensi, MengatasiTekanan Darah Tinggi. Jakarta: PT. Intisari Media Tama; 2007.

Casey A, Benson H. Menurunkan Tekanan Darah. Jakarta: PT. Bhuana Ilmu Popular; 2006.

Arifin MHBM, Weta IW, Ratnawati NLKA. Faktor-Faktor Yang Berhubungan Dengan Kejadian Hipertensi Pada kelompok Lanjut Usia Di Wilayah Kerja UPT Puskesmas Petang 1 Kabupaten Badung. E-Jurnal Med [Internet]. 2016;5(7):1–23. Available from: http://ojs.unud.ac.id/index.php/eum

Van Den Hoogen A, Krediet TG, Uiterwaal CSPM, Bolenius JFGA, Gerards LJ, Fleer A. In-line filters in central venous catheters in a neonatal intensive care unit. J Perinat Med. 2006;34(1):71–4.

Mayasari S. Analysis Of The Used Of Captopril Drug With Blood Pressure Of Hypertension Patients. J Kesehat dr Soebandi. 2020;8(2):123–7.

McCormack T, Krause T, O’Flynn N. Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract. 2012;62(596):163–4.

Kazerani H, Hajimoradi B, Amini A, Naseri MH, Moharamzad Y. Clinical efficacy of sublingual captopril in the treatment of hypertensive urgency. Singapore Med J. 2009;50(4):400–2.

Sandvik L, Erikssen J, Thaulow E, Erikssen G. The New England Journal of Medicine Downloaded from nejm.org at MCGILL UNIVERSITY LIBRARY on November 30, 2015. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights rese. Phys Fit as a Predict Mortal Men. 1993;328(8):2010–3.

Mousavi M, Razavianzadeh N, Armin M, Dashti MF. Sublingual versus oral captopril for decreasing blood pressure in hypertension urgency. Iran Red Crescent Med J. 2018;20(6).

Madinier I BN, Rm C. Drug-Induced Oral Ulcerations. Ann Med Interne. 2000;151:248–54.

PERKI. Pedoman Tatalaksana Sindroma Koroner Akut Edisi III. 2019.

PERKI. Pedoman Tatalaksana Sindroma Koroner Akut Edisi III. 2015. 13–14 p.

Sulistia Gan Gunawan. Farmakologi dan Terapi, 5th ed. In: 5Th ed. Jakarta: Fakultas Kesehatan Universitas Indonesia; 2008.

Palazzuoli A, Pellegrini M, Ruocco G, Martini G, Franci B, Campagna MS, et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: A prospective randomized trial. Crit Care. 2014;18(3):1–10.

Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail. 2011;13(11):1244–52.